Erectile dysfunction – a cardiologist’s point of view Review article
Article Sidebar
Published:
Mar 31, 2021
Keywords:
cardiosexuology, phosphodiesterase 5 inhibitors
Main Article Content
Abstract
Cardiovascular disease is a common phenomenon, just like obesity, arterial hypertension and diabetes. Those diseases negatively affect all spheres of our life, including our sex life. The best known currently is the relationship between the occurrence of erectile dysfunction and diseases of the cardiovascular system. Erectile dysfunction may not only be a late consequence cardiovascular diseases, but also their early revelator. However, they can also be a side effect of some cardiac medications. Cardiosexology deals with these issues. Perhaps, however, an even more important issue is the safety of treating erectile dysfunction in patients with cardiovascular diseases.
Article Details
How to Cite
Mamcarz , A., & Wełnicki , M. (2021). Erectile dysfunction – a cardiologist’s point of view. Medycyna Faktow (J EBM), 14(1(50), 32-35. https://doi.org/10.24292/01.MF.0121.3
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-6.
2. Eardley I. The incidence, prevalence and natural history of erectile dysfunction. Sex Med Rev. 2013; 1: 13-6.
3. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction. Results of the Cologne Male Survey. Int J Impot Res. 2000; 12: 305-11.
4. O’Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol. 2004; 39: 975-84.
5. Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005; 294: 2996-3002.
6. Hodges LD, Kirby M, Solanki J et al. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007; 61: 2019-25.
7. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011; 58: 1378-85.
8. Gong B, Ma M, Xie W et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta‑analysis. Int Urol Nephrol. 2017; 49: 1731-40. http://doi.org/10.1007/s11255-017-1644-5.
9. Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006; 61(3): 280‐8. http://doi.org/10.1111/j.1365-2125.2005.02553.x.
10. Young JM, Feldman RA, Auerbach SM et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl. 2005; 26(3): 310‐8. http://doi.org/10.2164/jandrol.04126.
11. Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010; 4: 159‐71. http://doi.org/10.2147/dddt.s9067.
12. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003; 92(9A): 47M‐57M. http://doi.org/10.1016/s0002-9149(03)00075-4.
13. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003; 92(9A): 37M‐46M. http://doi.org/10.1016/s0002-9149(03)00074-2.
14. Bocchio M, Pelliccione F, Passaquale G et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis. 2008; 196(1): 313‐9. http://doi.org/10.1016/j.atherosclerosis.2006.09.035.
15. Rosano GM, Aversa A, Vitale C et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005; 47(2): 214‐22. http://doi.org/10.1016/j.eururo.2004.10.002.
16. Manolis AJ, Doumas M, Viigimaa M et al. Hypertension and sexual dysfunction. Choroby Serca i Naczyń. 2007; 4: 65-9.
17. Jackson G, Rosen RC, Kloner RA et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006; 3: 28-3.
2. Eardley I. The incidence, prevalence and natural history of erectile dysfunction. Sex Med Rev. 2013; 1: 13-6.
3. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction. Results of the Cologne Male Survey. Int J Impot Res. 2000; 12: 305-11.
4. O’Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol. 2004; 39: 975-84.
5. Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005; 294: 2996-3002.
6. Hodges LD, Kirby M, Solanki J et al. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007; 61: 2019-25.
7. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011; 58: 1378-85.
8. Gong B, Ma M, Xie W et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta‑analysis. Int Urol Nephrol. 2017; 49: 1731-40. http://doi.org/10.1007/s11255-017-1644-5.
9. Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006; 61(3): 280‐8. http://doi.org/10.1111/j.1365-2125.2005.02553.x.
10. Young JM, Feldman RA, Auerbach SM et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl. 2005; 26(3): 310‐8. http://doi.org/10.2164/jandrol.04126.
11. Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010; 4: 159‐71. http://doi.org/10.2147/dddt.s9067.
12. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003; 92(9A): 47M‐57M. http://doi.org/10.1016/s0002-9149(03)00075-4.
13. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003; 92(9A): 37M‐46M. http://doi.org/10.1016/s0002-9149(03)00074-2.
14. Bocchio M, Pelliccione F, Passaquale G et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis. 2008; 196(1): 313‐9. http://doi.org/10.1016/j.atherosclerosis.2006.09.035.
15. Rosano GM, Aversa A, Vitale C et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005; 47(2): 214‐22. http://doi.org/10.1016/j.eururo.2004.10.002.
16. Manolis AJ, Doumas M, Viigimaa M et al. Hypertension and sexual dysfunction. Choroby Serca i Naczyń. 2007; 4: 65-9.
17. Jackson G, Rosen RC, Kloner RA et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006; 3: 28-3.